ICL vs GNVR vs BGM Stock Comparison

Icl, Genvor and Bgm Prices as of Oct 28, 2026 Peers: Industry group
ICL ICL Group Ltd.
$4.67 -7.0% 1M -29.7% 1Y
Market cap
$5.92B
P/E
8.6x
Revenue (TTM)
$7.71B
Div. yield
–
Fertilizers Basic Materials
3 wins
GNVR Genvor Inc
$0.75 -25.0% 1M -60.5% 1Y
Market cap
$27.31M
P/E
–
Revenue (TTM)
—
Div. yield
–
Crop Protection and Seeds Basic Materials
BGM BGM Group Ltd.
$9.26 +3,758.3% 1M -1.3% 1Y
Market cap
$34.96M
P/E
–
Revenue (TTM)
—
Div. yield
–
Generic Drugs Healthcare
1 win

Head to Head

4 decided of 12

Icl leads on 3 of the 12 questions below (Icl 3, Bgm 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLGNVRBGMLeader
Larger companyMarket capitalisation $5.92B $27.31M $34.96M ICL
Cheaper on earningsLower P/E, profitable companies only 8.6x -7.8x — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 11.7x — — –
Faster revenue growthRevenue growth, trailing twelve months +10.9% — — –
More profitableNet margin, trailing twelve months 9.0% — — –
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — — — –
Higher dividend yieldTrailing dividend yield 0.00% — 0.00% –
Better 1-year returnPrice return, last 12 months -29.7% -60.5% -1.3% BGM
Better 5-year returnAnnualised price return, 5 years -11.6%/yr — — –
Less volatileAnnualised volatility, 1 year 39.3% 280.2% 379.7% ICL
Higher overall scoreMean of the five percentile scores vs peers 82/100 12/100 — ICL

Percentile Scorecard

ICLGNVRBGM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLGNVRBGM
Valuation 98 #3 of 94 10 #85 of 94 –
Growth 48 #48 of 91 31 #63 of 91 –
Profitability 84 #14 of 84 – –
Financial Health – 0 #94 of 94 60 #263 of 654
Shareholder Returns 100 #1 of 69 9 #63 of 69 –
Overall 82 12 –
  • ICL ranked among 99 companies in Chemicals
  • GNVR ranked among 99 companies in Chemicals
  • BGM ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLGNVRBGMSPY
1 month -7.0%-25.0%+3,758.3% +0.9%
3 months -8.6%+36.4%+3,093.1% +5.9%
6 months -12.4%+25.0%+2,986.7% +8.5%
Year to date -18.2%-25.0%+150.9% +13.3%
1 year -29.7%-60.5%-1.3% +12.4%
3 years -2.9%—— +88.1%
3 years, per year -1.0%—— +23.5%
5 years -46.1%—— +68.2%
5 years, per year -11.6%—— +11.0%
10 years +29.7%—— +263.4%
10 years, per year +2.6%—— +13.8%

Risk

MeasureICLGNVRBGMSPY
Volatility, 1Y 39.3%280.2%379.7% 12.7%
Downside volatility, 1Y 45.2%460.5%158.2% 12.7%
Beta vs S&P 500, 1Y 0.76-0.631.76 1.00
Return / volatility, 1Y -0.75-0.220.00 0.98
Max drawdown, 5Y -70.0%-97.5%-98.5% -25.4%
From 52-week high -31.5%-62.5%-13.9% -0.9%
52-week high $6.82$2.00$10.75 $779.14
52-week low $4.67$0.20$0.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLGNVRBGM
P/E now vs peer median 8.7xmedian 22.0x -7.8xmedian 22.0x —median 17.4x
P/S now vs peer median 0.8xmedian 1.4x —median 1.4x —median 9.1x
EV/EBITDA now vs peer median —median 12.4x —median 12.4x —median 17.1x
P/FCF now vs peer median 5.1xmedian 15.5x -25.9xmedian 15.5x —median 19.0x
P/B now vs peer median —median 1.7x -10.1xmedian 1.7x 0.1xmedian 2.2x
PEG now vs peer median -0.53median 1.84 0.73median 1.84 —median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLGNVRBGM
Revenue $7.71B – –
Gross profit $2.36B – –
Operating income $715.00M -$4.01M –
Net income $654.00M -$3.45M –
Free cash flow $1.19B -$1.05M –
R&D – $386.20K –
EPS (diluted) $0.54 $-0.10 –
Cash & equivalents $496.00M $196.52K $11.52M
Total debt – $563.79K $8.25M
Shares (diluted) 1.29B 36.08M 3.78M
Enterprise value $2.61B $26.88M -$18.55M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLGNVRBGM
P/E 8.7x -7.8x –
P/FCF 5.1x -25.9x –
P/Operating cash flow – -25.9x –
P/S 0.8x – –
P/B – -10.1x 0.1x
P/Tangible book – -10.1x 0.1x
EV/EBITDA – – –
EV/EBIT 7.7x -6.9x –
EV/Revenue 0.7x – –
EV/FCF 4.7x -26.1x –
EV/Operating cash flow – -26.1x –
PEG (3Y EPS CAGR) -0.53 0.73 –

Growth

14 metrics
MetricICLGNVRBGM
Revenue growth (1Y) 10.9% – –
Revenue CAGR (3Y) 1.8% – –
Gross profit growth (1Y) 5.2% – –
Gross profit CAGR (3Y) 5.2% – –
Operating income growth (1Y) -1.7% 33.3% –
Operating income CAGR (3Y) -20.8% -55.6% –
Net income growth (1Y) -1.7% 41.0% –
Net income CAGR (3Y) -18.0% -38.4% –
EPS growth (1Y) 88.4% 55.1% –
EPS CAGR (3Y) -16.4% -10.7% –
Operating cash flow growth (1Y) – -151.3% –
Operating cash flow CAGR (3Y) – 1.7% –
Free cash flow growth (1Y) -17.5% -151.3% –
Free cash flow CAGR (3Y) -8.0% 1.7% –

Profitability

14 metrics
MetricICLGNVRBGM
Gross margin 30.6% – –
EBITDA margin – – –
Operating margin 9.3% – –
Pretax margin 9.9% – –
Net margin 9.0% – –
FCF margin 15.4% – –
Operating cash flow margin – – –
Return on equity – – –
Return on assets – -1,412% –
Return on invested capital – – –
Return on capital employed – – –
Asset turnover – – –
Cash conversion (OCF / net income) – 0.3x –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricICLGNVRBGM
Debt / assets – 117.2% 0.2%
Debt / equity – -0.1x 0.0x
Net debt / EBITDA – – –
Debt / FCF – -0.3x –
Liabilities / assets – 969.3% 8.4%
Equity / assets – -869.3% 91.6%
Interest coverage – -37.1x –
Current ratio – 0.1x 1.3x
Quick ratio – 0.1x 0.4x
Cash ratio – 0.1x 0.3x
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricICLGNVRBGM
Dividend yield 13.5% – –
Net buyback yield – -2.8% –
Shareholder yield 13.5% -2.8% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLGNVRBGM
Forward P/E 11.7xFY2026 – –
EPS, next fiscal year $0.40FY2026 – –
EPS growth, next FY +11.1%FY2026 – –
EPS growth, the year after +12.5% – –
Revenue, next fiscal year $7.47BFY2026 – –
Revenue growth, next FY +4.5%FY2026 – –
Revenue growth, the year after +13.0% – –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLGNVRBGM
Held by institutions 13.7% – –
Institutions holding 221 – –
Change in shares held, QoQ -13.5% – –
Institutions buying 140 – –
Institutions selling 56 – –
Buyers to sellers 2.50 – –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLGNVRBGM
ICL 1.00 0.04 -0.01
GNVR 0.04 1.00 -0.02
BGM -0.01 -0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICL, GNVR and BGM?

Icl (ICL) is the largest by market capitalisation: Icl (ICL) $5.92B, Genvor (GNVR) $27.31M, Bgm (BGM) $34.96M.

Which stock has performed better?

Over the past year Bgm (BGM) returned the most: Icl (ICL) -29.7%, Genvor (GNVR) -60.5%, Bgm (BGM) -1.3%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Icl (ICL) has been the steadiest (Icl (ICL) 39.3%, Genvor (GNVR) 280.2%, Bgm (BGM) 379.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICL, GNVR and BGM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Icl (ICL) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.